Skip to main content
    C

    Collplant Biotechnologies Ltd (CLGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.64
    -0.02 (-0.43%)

    Market Cap: $14.27M

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Collplant Biotechnologies Ltd (CLGN) Financials: Revenue, Profit and Cash Flow

    Updated Sep 30, 2026. Financial statements from company filings, amounts in US dollars.

    Collplant Biotechnologies reported revenue of $2.37M for the fiscal year ended Dec 31, 2025, up 360.4% from the year before. That year, net income was -$11.49M with a net margin of -484.6%, operating cash flow was -$9.42M and free cash flow was -$9.45M. The quarter ended Jun 30, 2026 had revenue of $108.00K and net income of -$2.73M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $75.91K, a compound annual rate of 46.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.37M+360.4%26.3%-484.3%-484.6%
    Dec 2024$515.00K-95.3%-417.1%-3349.7%-3225.0%
    Dec 2023$10.96M+3565.2%71.8%-68.5%-64.0%
    Dec 2022$299.00K-98.1%-393.6%-5718.1%-5660.5%
    Dec 2021$15.64M+154.9%87.2%0.4%1.5%
    Dec 2020$6.14M+164.8%43.7%-91.2%-94.1%
    Dec 2019$2.32M-51.6%18.9%-329.2%-481.6%
    Dec 2018$4.79M+897.8%65.0%N/A-130.5%
    Dec 2017$479.92K+532.2%32.8%N/A-1209.6%
    Dec 2016$75.91KN/A-196.3%N/A-9571.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$2.37M$515.00K$10.96M$299.00K$15.64M$6.14M$2.32M$4.79M$479.92K$75.91K
    Cost of revenue$1.75M$2.66M$3.09M$1.48M$2.00M$3.46M$1.88M$1.90M$306.09K$225.07K
    Gross profit$624.00K-$2.15M$7.87M-$1.18M$13.64M$2.68M$439.00K$3.11M$157.63K-$149.01K
    Research and development$8.19M$10.52M$10.48M$10.26M$7.63M$3.66M$4.41M$5.16M$4.05M$4.36M
    Operating income-$11.48M-$17.25M-$7.51M-$17.10M$65.00K-$5.60M-$7.63MN/AN/AN/A
    Net income-$11.49M-$16.61M-$7.02M-$16.93M$237.00K-$5.77M-$11.16M-$6.25M-$5.80M-$7.27M
    EBITDA-$10.56M-$15.55M-$5.91M-$15.81M$1.05M-$5.08MN/A-$5.88M-$5.47M-$7.03M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$108.00K$73.00K$60.00K$77.00K$179.00K$2.06M$164.00K$4.00K$249.00K$98.00K$299.00K$43.00K
    Gross profit-$653.00K-$243.00K-$348.00K-$415.00K-$236.00K$1.62M-$350.00K-$523.00K-$548.00K-$727.00K-$474.00K-$507.00K
    Operating income-$2.63M-$3.12M-$3.15M-$3.51M-$3.18M-$1.65M-$3.97M-$4.54M-$4.41M-$4.33M-$5.07M-$4.60M
    Net income-$2.73M-$3.10M-$3.21M-$3.48M-$3.35M-$1.45M-$3.88M-$4.33M-$4.21M-$4.20M-$4.69M-$4.38M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $814.00K by $5.14M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$10.79M$18.71M$34.13M$37.77M$51.22M$10.84M$10.75M$9.05M$8.07M$3.75M
    Current assets$6.75M$13.18M$28.02M$31.66M$45.09M$5.68M$5.04M$7.14M$6.45M$2.10M
    Cash and equivalents$5.95M$11.91M$26.67M$29.65M$13.15M$3.33M$3.79M$5.33M$5.13M$987.11K
    Total liabilities$4.70M$5.25M$5.79M$5.49M$6.10M$6.36M$6.66M$4.29M$5.46M$2.41M
    Short-term debt$814.00K$806.00K$624.00K$529.00K$519.00K$440.00K$479.00K$22.00KN/A$0
    Shareholder equity$6.08M$13.46M$28.34M$32.28M$45.12M$4.48M$4.09M$4.76M$2.61M$1.34M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$7.20M$9.18M$10.79M$14.09M$17.44M$17.21M$18.71M$22.44M$26.57M$30.29M$34.13M$37.56M
    Total liabilities$4.25M$4.30M$4.70M$4.78M$4.93M$4.81M$5.25M$5.52M$5.84M$5.85M$5.79M$5.16M
    Cash and equivalents$2.95M$4.26M$5.95M$8.55M$11.71M$10.73M$11.91M$15.37M$18.92M$23.46M$26.67M$28.98M
    Shareholder equity$2.94M$4.89M$6.08M$9.30M$12.51M$12.40M$13.46M$16.92M$20.73M$24.45M$28.34M$32.40M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$9.42M-$14.09M-$2.76M-$13.70M$2.50M-$4.45M-$5.70M-$1.22M-$4.97M-$5.02M
    Capital expenditures$28.00K$483.00K$954.00K$1.27M$1.43M$437.00K$1.49M$832.00K$127.00K$127.70K
    Free cash flow-$9.45M-$14.58M-$3.72M-$14.97M$1.07M-$4.89M-$7.19M-$2.05M-$5.09M-$5.15M
    Investing cash flow-$27.00K-$539.00K-$1.16M$28.92M-$31.56M-$519.00K-$1.46M-$832.00K-$127.00K-$127.70K
    Financing cash flow$3.10M$9.00K$1.11M$1.87M$38.76M$4.46M$5.41M$2.75M$9.11M$4.80M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$2.47M-$3.05M-$3.21M-$2.88M-$2.44M-$1.17M-$3.46M-$3.45M-$3.93M-$3.25M-$2.35M$6.78M
    Capital expenditures$70.93K$6.00K$16.11K$1.00K$3.00K$9.00K$59.00K$140.00K$202.00K$82.00K$229.00K$243.00K
    Free cash flow-$2.54M-$3.06M-$3.23M-$2.88M-$2.44M-$1.18M-$3.52M-$3.59M-$4.13M-$3.33M-$2.57M$6.53M
    Last 12 quarters

    Frequently Asked Questions About CLGN

    What is Collplant Biotechnologies' annual revenue?

    Collplant Biotechnologies reported revenue of $2.37M for the fiscal year ended Dec 31, 2025.

    How fast is Collplant Biotechnologies' revenue growing?

    Revenue was up 360.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 99.4%.

    Is Collplant Biotechnologies profitable?

    No. Collplant Biotechnologies reported net income of -$11.49M for the fiscal year ended Dec 31, 2025, with a net margin of -484.6%.

    How much free cash flow does CLGN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.42M minus capital expenditures of $28.00K produced free cash flow of -$9.45M.

    How much debt does Collplant Biotechnologies have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $814.00K and cash and equivalents of $5.95M.